Thomas, F.(1), S Séronie-Vivien(1), F Bouissou(2), M Tafani(2), JP Delord(1), L Gladieff(1), E Chatelut(1) Cystatin C as a new covariate to predict the renal elimination of drugs
|
Roy, A. and M. Pfister Optimizing Dose Selection With Respect to Multiple Safety/Efficacy Endpoints Using Clinical Utility Concepts
|
Elsherbiny, D.(1), S. Asimus(2), M.O. Karlsson(1), M. Ashton(2), U. S. H. Simonsson(1) Modeling of the induction of CYP2B6 and CYP2C19 by artemisinin antimalarials
|
Mondick, John T.(1), Leonid Gibiansky (2), Marc R. Gastonguay (2), Gareth J. Veal (3), Jeffrey S. Barrett (1) Acknowledging Parameter Uncertainty in the Simulation-Based Design of an Actinomycin-D Pharmacokinetic Study in Pediatric Patients with Wilms’ Tumor or Rhabdomyosarcoma
|
Kowalski, Kenneth G., Stephen Olson, Ann Remmers A Modeling and Simulation Case Study: Impact on an Early Clinical Development Program
|
Gibiansky, Ekaterina (1), Leonid Gibiansky (2) Model-Based Drug Development: Optimization of AQUAVAN® Injection Dosing for Minimal-to-Moderate Sedation
|
Viberg, Anders (1), Otto Cars (2), Mats O. Karlsson (1) and Siv Jönsson (3) Individualization of Cefuroxime Dosage using Pharmacodynamic targets, MIC distributions and Minimization of a Risk Function
|
Woltosz, Walter S. and Michael B. Bolger Simulation of the Nonlinear PK of Gabapentin and Midazolam in Adult and Pediatric Populations
|
Edginton, A.N.(1), S. Willmann (1), Sevestre, M (2), Kirchheiner, J (3) Determining the effect of CYP2C9 genotypes on diclofenac metabolism using individualized coupled physiology-based pharmacokinetic modeling
|